Francesco Passamonti, MD, University of Insubria, Varese, Italy, discusses the first-line treatment of myelofibrosis (MF), commenting on the use of hematopoietic stem cell transplantation (HSCT) and JAK inhibitors like ruxolitinib and fedratinib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
